Radretumab Biosimilar – Anti-FN EDB mAb – Research Grade

Description of Radretumab Biosimilar - Anti-FN EDB mAb - Research Grade

Introduction

Radretumab Biosimilar, also known as Anti-FN EDB mAb, is a novel therapeutic agent that has been developed as a biosimilar of the monoclonal antibody radretumab. This biosimilar is designed to specifically target the fibronectin extra domain B (EDB), a protein that is overexpressed in many types of cancer. In this article, we will discuss the structure, activity, and potential applications of Radretumab Biosimilar in research.

Structure of Radretumab Biosimilar

Radretumab Biosimilar is a recombinant humanized monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL2) and one variable domain (VL). The variable domains of Radretumab Biosimilar are responsible for binding to the EDB protein, while the constant domains provide stability and effector functions.

Activity of Radretumab Biosimilar

Radretumab Biosimilar specifically targets the EDB protein, which is a splice variant of fibronectin that is only expressed in the extracellular matrix of tumor tissues. This protein is involved in tumor growth, invasion, and metastasis, making it an attractive therapeutic target. Radretumab Biosimilar binds to the EDB protein with high affinity and blocks its interaction with other proteins, thereby inhibiting tumor growth and metastasis.

In addition to its direct anti-tumor activity, Radretumab Biosimilar also has immune-modulating effects. It can activate natural killer (NK) cells and macrophages, which are important components of the body’s immune system. This activation leads to the destruction of tumor cells and enhances the overall anti-tumor response.

Applications in Research

Radretumab Biosimilar has potential applications in various areas of cancer research. Its ability to specifically target the EDB protein makes it a valuable tool for studying the role of this protein in cancer progression. It can also be used to investigate the mechanisms of action of other anti-cancer therapies and to identify potential biomarkers for predicting response to treatment.

Moreover, Radretumab Biosimilar can be used in preclinical studies to evaluate its efficacy and safety in different tumor models. These studies can provide valuable information for the development of clinical trials and the optimization of treatment protocols.

Furthermore, Radretumab Biosimilar can be used in combination with other anti-cancer therapies to enhance their efficacy. Its immune-modulating effects can improve the response to immunotherapy and other targeted therapies, making it a promising candidate for combination treatments.

Conclusion

In summary, Radretumab Biosimilar is a novel biosimilar of the monoclonal antibody radretumab, designed to specifically target the EDB protein in cancer. Its unique structure and activity make it a valuable tool for cancer research, with potential applications in studying the role of EDB in cancer progression, evaluating its efficacy and safety in preclinical studies, and enhancing the efficacy of other anti-cancer therapies. Further clinical studies are needed to fully explore the potential of Radretumab Biosimilar as a therapeutic agent for cancer treatment.